The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs.
The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs.
复制标题
ΔF508突变会导致CFTR错误处理和猪的囊性纤维化样疾病。
DOI:
10.1126/scitranslmed.3001868
复制
发表时间:
2011-03-16
影响因子:
17.1
通讯作者:
Stoltz DA
中科院分区:
文献类型:
--
作者:
Ostedgaard LS;Meyerholz DK;Chen JH;Pezzulo AA;Karp PH;Rokhlina T;Ernst SE;Hanfland RA;Reznikov LR;Ludwig PS;Rogan MP;Davis GJ;Dohrn CL;Wohlford-Lenane C;Taft PJ;Rector MV;Hornick E;Nassar BS;Samuel M;Zhang Y;Richter SS;Uc A;Shilyansky J;Prather RS;McCray PB Jr;Zabner J;Welsh MJ;Stoltz DA
Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel cause the autosomal recessive disease, cystic fibrosis (CF). The most common mutation is ΔF508, which deletes phenylalanine508. In vitro studies indicate that CFTR-ΔF508 is misprocessed, though in vivo consequences of the mutation are uncertain. To better understand effects of the ΔF508 mutation, we produced CFTRΔF508/ΔF508 pigs. Our biochemical, immunocytochemical and electrophysiological data on CFTR-ΔF508 in newborn pigs paralleled in vitro results. They also indicated that CFTRΔF508/ΔF508 airway epithelia retain a small residual CFTR conductance; maximal stimulation produced ~6% of wild-type function. Interestingly, cAMP agonists were less potent at stimulating current in CFTRΔF508/ΔF508 epithelia, suggesting that quantitative tests of maximal anion current may overestimate transport under physiological conditions. Despite residual CFTR function, four older CFTRΔF508/ΔF508 pigs developed lung disease strikingly similar to human CF. These results suggest that this limited CFTR activity is insufficient to prevent lung or gastrointestinal disease in CF pigs. These data also suggest that studies of recombinant CFTR-ΔF508 misprocessing predict in vivo behavior, which validates its use in biochemical and drug discovery experiments. These findings help elucidate the molecular pathogenesis of the common CF mutation and will guide strategies for developing new therapeutics.
登录
查看更多内容
DOI:
10.1085/jgp.200409059
发表时间:
2004-08
期刊:
The Journal of general physiology
影响因子:
--
作者:
Muanprasat C;Sonawane ND;Salinas D;Taddei A;Galietta LJ;Verkman AS
通讯作者:
Verkman AS
DOI:
10.1126/science.1191542
发表时间:
2010-08-13
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Okiyoneda T;Barrière H;Bagdány M;Rabeh WM;Du K;Höhfeld J;Young JC;Lukacs GL
通讯作者:
Lukacs GL
影响因子:
24.3
作者:
Ho, LP;Samways, JM;Innes, JA
通讯作者:
Innes, JA
DOI:
10.1124/jpet.109.162032
发表时间:
2010-04-01
影响因子:
3.5
作者:
Kelly, Mairead;Trudel, Stephanie;Fritsch, Janine
通讯作者:
Fritsch, Janine
DOI:
10.1165/rcmb.2008-0434oc
发表时间:
2010-03-01
影响因子:
6.4
作者:
Jurkuvenaite, Asta;Chen, Lan;Collawn, James F.
通讯作者:
Collawn, James F.